GenesisCare

Neal Shore, MD, FACS, discussed a study on survival outcomes in metastatic castration-sensitive prostate cancer comparing apalutamide with abiraterone acetate.

In an interview with Targeted Oncology, Neal Shore, MD, FACS, discussed the background, findings, and implications of a real-world study of enzalutamide and apalutamide in patients with metastatic castration-sensitive prostate cancer.

Neal Shore, MD, FACS, discusses a study aimed to investigate the real-world survival outcomes of men with metastatic castration-sensitive prostate cancer treated with either apalutamide or enzalutamide in the United States.

It was announced that the phase 3 EMBARK study met its primary end point in patients with nonmetastatic castration-sensitive prostate cancer with high-risk biochemical recurrence.

Treatment with TARA-002 at 3 different dose levels was generally well-tolerated, and no dose limiting toxicities were observed among patients with high-grade non-muscle invasive bladder cancer.

In an interview with Targeted Oncology, Bridget Koontz, MD, discussed burnout and its importance in experts treating patients with cancer.

Neal Shore, MD, discusses the long-term exposure analysis of darolutamide in the phase 3 ARAMIS Rollover trial for patients with nonmetastatic castration-resistant prostate cancer.

John E. Sylvester, MD, a radiation oncologist with GenesisCare, reviews the importance of treating prostate cancer at the earliest stage possible.

For Breast Cancer Awareness Month Kristina Mirabeau-Beale, mD, MPH, and Bridget Koontz, MD, discuss the different types of breast cancer that clinicians need to be aware of.

For Gynecologic Cancer Awareness Month, Dr. Sonal Sura discusses the recent progress in the treatment of patients with cervical cancer.

Niraj H. Mehta, MD, reviews the areas of the body where skin cancer can be hard to detect, what the skin cancer will look like on those parts of the body, risk factors for those receiving treatment, and follow-up for patients to catch recurrences.

Results from a post-hoc analysis of ARCHES showed that the enzalutamide plus ADT significantly improved survival, as well as key secondary end points, compared with placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer.

Neal Shore, MD, FACS discusses results from a post-hoc analysis of the phase 3 ARCHES trial.

In an interview with Targeted Oncology, Bridget Koontz, MD, United States chief medical officer and deputy global chief medical officer at GenesisCare, discusses 18F-DCFPyL and how the well-tolerated agent can change the way prostate cancer patients are treated

In its new Sunnyvale, Texas location, GenesisCare offers comprehensive patient-centered services for patients with breast cancer.

GenesisCare and Lee Health announce their efforts to transform pancreatic patient survival rates in Florida.